Immune responses to vaccines involving a combined antigen-nanoparticle mixture and nanoparticle-encapsulated antigen formulation.

Many physicochemical characteristics significantly influence the adjuvant effect of micro/nanoparticles; one critical factor is the kinetics of antigen exposure to the immune system by particle-adjuvanted vaccines. Here, we investigated how various antigen-nanoparticle formulations impacted antigen exposure to the immune system and the resultant antigen-specific immune responses. We formulated antigen with poly(lactic-co-glycolic acid) (PLGA) nanoparticles by encapsulating antigen within nanoparticles or by simply mixing soluble antigen with the nanoparticles. Our results indicated that the combined formulation (composed of antigen encapsulated in nanoparticles and antigen mixed with nanoparticles) induced more powerful antigen-specific immune responses than each single-component formulation. Mice immunized with the combined vaccine formulation displayed enhanced induction of antigen-specific IgG antibodies with high avidity, increased cytokine secretion by splenocytes, and improved generation of memory T cell. Enhanced immune responses elicited by the combined vaccine formulation might be attributed to the antigen-depot effect at the injection site, effective provision of both adequate initial antigen exposure and long-term antigen persistence, and efficient induction of dendritic cell (DC) activation and follicular helper T cell differentiation in draining lymph nodes. Understanding the effect of antigen-nanoparticle formulations on the resultant immune responses might have significant implications for rational vaccine design.

[1]  P. Marrack,et al.  Towards an understanding of the adjuvant action of aluminium , 2009, Nature Reviews Immunology.

[2]  J. Kreuter,et al.  New adjuvants on a polymethylmethacrylate base , 1976, Infection and immunity.

[3]  Lihua Wu,et al.  Paclitaxel acts as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. , 2010, Vaccine.

[4]  Christophe Benoist,et al.  Antigen persistence is required throughout the expansion phase of a CD4+ T cell response , 2005, The Journal of experimental medicine.

[5]  H. Alpár,et al.  Potential use of nanoparticles for transcutaneous vaccine delivery: effect of particle size and charge. , 2004, International journal of pharmaceutics.

[6]  E. Wherry,et al.  Vaccines: Effector and memory T-cell differentiation: implications for vaccine development , 2002, Nature Reviews Immunology.

[7]  D. Irvine,et al.  Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction , 2012, Proceedings of the National Academy of Sciences.

[8]  Joel A. Cohen,et al.  Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy , 2009, Proceedings of the National Academy of Sciences.

[9]  Sven Frokjaer,et al.  Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. , 2005, International journal of pharmaceutics.

[10]  Martin F. Bachmann,et al.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.

[11]  Yvonne Perrie,et al.  Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[12]  D. Turner,et al.  Duration of Antigen Availability Influences the Expansion and Memory Differentiation of T Cells , 2011, The Journal of Immunology.

[13]  N. Van Rooijen,et al.  Prolonged Antigen Presentation Is Required for Optimal CD8+ T Cell Responses against Malaria Liver Stage Parasites , 2010, PLoS pathogens.

[14]  W. Oyen,et al.  Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients , 2011, Clinical Cancer Research.

[15]  Bali Pulendran,et al.  Immunological mechanisms of vaccination , 2011, Nature Immunology.

[16]  O. Lantz,et al.  Antigen Persistence Is Required for Dendritic Cell Licensing and CD8+ T Cell Cross-Priming1 , 2008, The Journal of Immunology.

[17]  Rino Rappuoli,et al.  Vaccine manufacturing: challenges and solutions , 2006, Nature Biotechnology.

[18]  J. Buer,et al.  The use of calcium phosphate nanoparticles encapsulating Toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation. , 2010, Biomaterials.

[19]  Zhengrong Cui,et al.  Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses , 2010, Expert review of vaccines.

[20]  V. Kanchan,et al.  Memory antibody response from antigen loaded polymer particles and the effect of antigen release kinetics. , 2009, Biomaterials.

[21]  T. Kündig,et al.  Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[22]  J. Schlom,et al.  Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. , 2007, Vaccine.

[23]  R. R. Anderson,et al.  A Novel Laser Vaccine Adjuvant Increases the Motility of Antigen Presenting Cells , 2010, PloS one.

[24]  Eric Stern,et al.  Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. , 2012, Biomaterials.

[25]  T. Rades,et al.  Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[26]  S. Tangye,et al.  Follicular helper T cell differentiation requires continuous antigen presentation that is independent of unique B cell signaling. , 2010, Immunity.

[27]  Polly Matzinger,et al.  Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses , 2004, Nature Reviews Immunology.

[28]  Dan Peer,et al.  Nanoparticle hydrophobicity dictates immune response. , 2012, Journal of the American Chemical Society.

[29]  C. Vinuesa,et al.  The elusive identity of T follicular helper cells. , 2010, Trends in immunology.

[30]  G. Ma,et al.  Comparison of PLA Microparticles and Alum as Adjuvants for H5N1 Influenza Split Vaccine: Adjuvanticity Evaluation and Preliminary Action Mode Analysis , 2013, Pharmaceutical Research.

[31]  D. Irvine,et al.  Particulate vaccines: on the quest for optimal delivery and immune response. , 2011, Drug discovery today.

[32]  T. Kündig,et al.  Antigen kinetics determines immune reactivity , 2008, Proceedings of the National Academy of Sciences.

[33]  L. Malherbe,et al.  Regulation of CD4 T‐cell receptor diversity by vaccine adjuvants , 2010, Immunology.

[34]  R. Melamed,et al.  Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activation , 2007, Proceedings of the National Academy of Sciences.

[35]  Derek T. O'Hagan,et al.  Recent Advances in Vaccine Adjuvants , 2002, Pharmaceutical Research.